Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT) (Q33556796)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q37391755)
(Q41640212)
(Q61337175)
(Q64431345)
(Q64427353)
(P275) (Q19125045)
(P304) 177-183
(P407) (Q1860)
(P433) 1
(P478) 33
(P577) Tuesday, October 6, 2009
(P921) (Q19484)
(Q3403879)
(Q424771)
(P1433) (Q5270111)
(P1476) "Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)" (language: en)
(P2093) Giancarlo Viberti
Barbara G Kravitz
Dahong Yu
Gitanjali Paul
Rury R Holman
Diabetes Outcome Progression Trial (ADOPT) Study Group
(P2860) (Q28236480)
(Q34634794)
(Q22250883)
(Q28295023)
(Q29620534)
(Q34572519)
(Q29619886)
(Q34225645)
(Q34325011)
(Q34311841)
(Q34142970)
(Q29619398)
(Q28184413)
(Q33942737)
(Q42487208)
(Q37878667)
(Q51484209)
(Q51493750)
(Q51797108)
(Q46570674)
(Q44671845)
(Q44513183)
(Q46005836)
(Q44287903)
(Q44216708)
(Q44155654)
(Q43935468)
(Q43903149)
(Q42517667)
(Q43876922)
(Q51555318)
(Q57830181)
(Q81287307)
(Q79849283)
(Q80015974)
(P6216) (Q50423863)
other details
description scientific article

External Links